Literature DB >> 23241566

Hypertension: Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure guidelines.

Daniel T Lackland1.   

Abstract

PURPOSE OF REVIEW: Hypertension has been recognized for decades as a major factor for stroke, with observational epidemiologic studies clearly identifying the increased stroke risks with blood pressure (BP) levels and randomized controlled clinical trials providing evidence of stroke risk reduction with lower BPs. Hypertension treatment and management guidelines, the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC) reports, have recognized the high impact of elevated BPs and influenced lower BPs with subsequent stroke risk reduction. In particular, the previous seven JNC reports included an evolution of SBP levels for treatment. This review addresses the influences of the JNC reports on stroke outcomes and describes the potential efforts of the upcoming guidelines. RECENT
FINDINGS: The recommendations of lower SBPs from the earlier reports were consistent with lower population BP shifts during the time period. The next JNC report will have a major focus on graded evidence from randomized clinical trials with detailed strategies and subsequent impact on stroke risks.
SUMMARY: The impact of the evidence-based guidelines will be expected to have enhanced effects on stroke rates by providing clinicians with current treatment and management recommendations.

Entities:  

Mesh:

Year:  2013        PMID: 23241566     DOI: 10.1097/WCO.0b013e32835c4f54

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  5 in total

1.  Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.

Authors:  Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner
Journal:  Circulation       Date:  2017-06-20       Impact factor: 29.690

Review 2.  Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

Authors:  Ali Nehme; Kazem Zibara
Journal:  Hypertens Res       Date:  2017-07-06       Impact factor: 3.872

Review 3.  Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Authors:  Hyungseop Kim; Woo-Baek Chung; Kyoung Im Cho; Bong-Joon Kim; Jeong-Sook Seo; Seong-Mi Park; Hak Jin Kim; Ju-Hee Lee; Eun Kyoung Kim; Ho-Joong Youn
Journal:  J Cardiovasc Ultrasound       Date:  2018-03-28

4.  Valsartan recall: global regulatory overview and future challenges.

Authors:  Muhammad Junaid Farrukh; Muhammad Haseeb Tariq; Obaidullah Malik; Tahir Mehmood Khan
Journal:  Ther Adv Drug Saf       Date:  2019-01-18

Review 5.  Role of environmental toxicants in the development of hypertensive and cardiovascular diseases.

Authors:  Ehsan Habeeb; Saad Aldosari; Shakil A Saghir; Mariam Cheema; Tahani Momenah; Kazim Husain; Yadollah Omidi; Syed A A Rizvi; Muhammad Akram; Rais A Ansari
Journal:  Toxicol Rep       Date:  2022-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.